본문 바로가기
KERD
논문KCI 등재

Haplotype Association of the MAP2K5 Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류정신과학

초록

Objective Restless legs syndrome (RLS) is considered a genetic disease and, following a genome-wide association study conducted in 2007, the mitogen-activated protein kinase 5 (MAP2K5) gene has been regarded as the promising candidate gene for RLS. The present study investigated whether polymorphisms of MAP2K5 are associated with antipsychotics-induced RLS in schizophrenia. Methods We assessed antipsychotics-induced RLS symptoms in 190 Korean schizophrenic patients using the diagnostic criteria of the International Restless Legs Syndrome Study Group. Five single-nucleotide polymorphisms (SNPs) of MAP2K5 were genotyped. We investigated genetic and haplotypic associations of these five SNPs with the risk of antipsychotics-induced RLS symptoms. Results We divided the 190 subjects into 2 groups: 1) those with RLS symptoms (n=96) and 2) those without RLS symptoms (n=94). There were no significant intergroup differences in the distributions of the genotypes and alleles of the rs1026732, rs11635424, rs12593813, rs4489954, and rs3784709 SNPs. However, the haplotype analysis showed that the G-G-G-G-T (rs1026732-rs11635424-rs12593813-rs4489954-rs3784709) haplotype was associated with RLS symptoms (permutation p=0.033). Conclusion These data suggest that a haplotype of MAP2K5 polymorphisms confers increased susceptibility to antipsychotics-induced RLS symptoms in schizophrenic patients.

Abstract

Objective Restless legs syndrome (RLS) is considered a genetic disease and, following a genome-wide association study conducted in 2007, the mitogen-activated protein kinase 5 (MAP2K5) gene has been regarded as the promising candidate gene for RLS. The present study investigated whether polymorphisms of MAP2K5 are associated with antipsychotics-induced RLS in schizophrenia. Methods We assessed antipsychotics-induced RLS symptoms in 190 Korean schizophrenic patients using the diagnostic criteria of the International Restless Legs Syndrome Study Group. Five single-nucleotide polymorphisms (SNPs) of MAP2K5 were genotyped. We investigated genetic and haplotypic associations of these five SNPs with the risk of antipsychotics-induced RLS symptoms. Results We divided the 190 subjects into 2 groups: 1) those with RLS symptoms (n=96) and 2) those without RLS symptoms (n=94). There were no significant intergroup differences in the distributions of the genotypes and alleles of the rs1026732, rs11635424, rs12593813, rs4489954, and rs3784709 SNPs. However, the haplotype analysis showed that the G-G-G-G-T (rs1026732-rs11635424-rs12593813-rs4489954-rs3784709) haplotype was associated with RLS symptoms (permutation p=0.033). Conclusion These data suggest that a haplotype of MAP2K5 polymorphisms confers increased susceptibility to antipsychotics-induced RLS symptoms in schizophrenic patients.

참고문헌 (43)

  1. Phillips B, "Epidemiology of restless legs symptoms in adults", Arch Intern Med, 160, pp.2137~2141 (2000)[DOI]
  2. Oka Y, "Secondary restless legs syndrome", Brain Nerve, 61, pp.539~547 (2009)
  3. Kang SG, "Characteristics and clinical correlates of restless legs syndrome in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1078~1083 (2007)[DOI]
  4. Aggarwal S, "Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implications", Curr Drug Saf, 10, pp.98~105 (2015)[DOI]
  5. Winkelman JW, "Foundations of Psychiatric Sleep Medicine" (2010), Cambridge University Press
  6. Pichler I, "Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate", Am J Hum Genet, 79, pp.716~723 (2006)[DOI]
  7. Chen S, "Genomewide linkage scan identifies a novel susceptibility locus for RLS on chromosome 9p", Am J Hum Genet, 74, pp.876~885 (2004)[DOI]
  8. Desautels A, "Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity", Arch Neurol, 62, pp.591~596 (2005)[DOI]
  9. Levchenko A, "The 14q restless legs syndrome locus in the French Canadian population", Ann Neurol, 55, pp.887~891 (2004)[DOI]
  10. Kemlink D, "Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13", Neurogenetics, 9, pp.75~82 (2008)[DOI]
  11. Levchenko A, "A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13", Neurology, 67, pp.900~901 (2006)[DOI]
  12. Levchenko A, "Autosomal-dominant locus for Restless Legs Syndrome in French- Canadians on chromosome 16p12.1", Mov Disord, 24, pp.40~50 (2009)[DOI]
  13. Stefansson H, "A genetic risk factor for periodic limb movements in sleep", N Engl J Med, 357, pp.639~647 (2007)[DOI]
  14. Winkelmann J, "Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions", Nat Genet, 39, pp.1000~1006 (2007)[DOI]
  15. Kang SG, "Possible association between G-protein <TEX>${\beta}3$<", TEX> subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia, 2007, pp.19, 351~356
  16. Kang SG, "Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia", Neuropsychobiology, 57, pp.49~54 (2008)[DOI]
  17. Kang SG, "Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia", Hum Psychopharmacol, 25, pp.397~403 (2010)[DOI]
  18. 조철현, "Association between Antipsychotics-Induced Restless Legs Syndrome and Tyrosine Hydroxylase Gene Polymorphism", PSYCHIATRY INVESTIGATION, 6(3), pp.211~215 (2009), 대한신경정신의학회
  19. Kang SG, "The BTBD9 gene may be associated with antipsychotic-induced restless legs syndrome in schizophrenia", Hum Psychopharmacol, 28, pp.117~123 (2013)[DOI]
  20. Jung JS, "Association between restless legs syndrome and CLOCK and NPAS2 gene polymorphisms in schizophrenia", Chronobiol Int, 31, pp.838~844 (2014)[DOI]
  21. 강승걸, "MEIS1, a Promising Candidate Gene, Is Not Associated with the Core Symptoms of Antipsychotic-Induced Restless Legs Syndrome in Korean Schizophrenia Patients", PSYCHIATRY INVESTIGATION, 12(2), pp.263~267 (2015), 대한신경정신의학회[DOI]
  22. Han OS, "Structured Clinical Interview for DSM-IV Axis I Disorder-Korean Version" (2000), Hana Medical Publishing
  23. American Psychiatric Association, "Practice Guidelines for the Treatment of Patients with Schizophrenia" (1997), American Psychiatric Press
  24. Bazire S, "Psychotropic Drug Directory. The Professionals' Pocket Handbook and Aide Memoire" (2005), Fivepin
  25. Hales RE, "Textbook of Clinical Psychiatry, Fourth Ed." (2002), American Psychiatric Publishing
  26. Inagaki A, "Dose Equivalence of Psychotic Drugs" (1999), Seiwa Press
  27. Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)[DOI]
  28. Allen RP, "Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless leg syndrome diagnosis and epidemiology workshop at the National Institute of Health", Sleep Med, 4, pp.101~119 (2003)[DOI]
  29. Walters AS, "Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome", Sleep Med, 4, pp.121~132 (2003)[DOI]
  30. Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, pp.672~676 (1989)
  31. Lin CH, "Association of candidate genetic variants with restless legs syndrome in end stage renal disease: a multicenter case-control study in Taiwan", Eur J Neurol, 21, pp.492~498 (2014)[DOI]
  32. Klingaman EA, "Sleep disorders among people with schizophrenia: emerging research", Curr Psychiatry Rep, 17, pp.79~ (2015)[DOI]
  33. Kemlink D, "Replication of restless legs syndrome loci in three European populations", J Med Genet, 46, pp.315~318 (2009)[DOI]
  34. Moore H 4th, "Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3", BC034767, MEIS1, MAP2K5, Sleep, pp.2014, 37[DOI]
  35. Yang Q, "Association studies of variants in MEIS1, BTBD9, and MAP2K5", SKOR1 with restless legs syndrome in a US population, 2011, pp.12, 800~804
  36. Zhou G, "Components of a new human protein kinase signal transduction pathway", J Biol Chem, 270, pp.12665~12669 (1995)[DOI]
  37. Dinev D, "Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells", EMBO Rep, 2, pp.829~834 (2001)[DOI]
  38. Cavanaugh JE, "Neuroprotective role of ERK1", 2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress, 2006, pp.84, 1367~1375
  39. Hening WA, "Current guidelines and standards of practice for restless legs syndrome", Am J Med, 120(1 Suppl 1), pp.S22~S27 (2007)[DOI]
  40. Mignot E, "A step forward for restless legs syndrome", Nat Genet, 39, pp.938~939 (2007)[DOI]
  41. Winkelmann J, "Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1", PLoS Genet, 7, pp.e1002171~ (2011)[DOI]
  42. Vilarino-Guell C, "A genetic risk factor for periodic limb movements in sleep", N Engl J Med, 358, pp.425~427 (2008)[DOI]
  43. Kim MK, "Association of restless legs syndrome variants in Korean patients with restless legs syndrome", Sleep, 36, pp.1787~1791 (2013)[DOI]

관련 논문AI추천

이 간행물의 다른 논문 (16건)